AMO Development, LLC, contends a high-energy ablating ultraviolet laser can’t correct internal eye problems because it would first destroy corneal tissue because “laser pulses are highly absorbed in whatever tissue they first encounter.” The U.S. Patent Trial and Appeal Board agreed in IPR2021-00856. Alcon Inc., Alcon Vision, LLC, Alcon Laboratories, Inc., and Alcon Research, LLC,…
This content is viewable by members only. Visit MY ACCOUNT on the top menu to log in or to register for a 30 day free trial or purchase a subscription for UV Reporter 1 Year Single Membership or UV Reporter 1 Year Group Membership - $189 for first member and $25 for each additional member.
